Back to Search
Start Over
Modulation of the extinction of two different fear-motivated tasks in three distinct brain areas.
- Source :
-
Behavioural brain research [Behav Brain Res] 2012 Jun 15; Vol. 232 (1), pp. 210-6. Date of Electronic Publication: 2012 Apr 13. - Publication Year :
- 2012
-
Abstract
- The hippocampus, basolateral amygdala and ventromedial prefrontal cortex participate in the extinction of inhibitory avoidance and contextual fear conditioning. We studied the effect of drugs acting on receptors involved in synaptic modulation on extinction of both tasks. The drugs were given bilaterally right after the first of two sessions of extinction in each task through cannulae implanted into the mentioned areas. The doses used are known to influence memory consolidation of the original tasks. Their effects were evaluated on a second extinction session 24h later, and assumed to result from influences on the consolidation of extinction. The glutamate NMDA receptor stimulant d-serine (50 μg/side) and the histamine methyl-transferase inhibitor SKF9188 (12.5 μg/side) enhanced, and the NMDA antagonist amino-phosphonopentanoate (5 μg/side) and the H2 histamine receptor antagonist ranitidine (17.5 μg/side) inhibited, extinction of both tasks regardless of the region into which they were administered. Thus, glutamate NMDA receptors are involved in the consolidation of extinction of both tasks, and histamine H2 receptors modulate that process in all areas studied. Norepinephrine (1 μg/side), the β-adrenoceptor antagonist timolol (1 μg/side), the D1 dopamine receptor agonist SKF38393 (12.5 μg/side) and the D1 antagonist SCH23390 (1.5 μg/side) also affected extinction of both tasks, but their effects varied with the task and with the site of infusion, suggesting that extinction modulation by β- and D1 receptors is more complex. In conclusion, extinction of two different aversive tasks is modulatable by various systems, which bears upon the behavioral and pharmacological treatment of fear-motivated brain disorders.<br /> (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Subjects :
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine administration & dosage
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine pharmacology
2-Amino-5-phosphonovalerate administration & dosage
2-Amino-5-phosphonovalerate pharmacology
Adrenergic beta-Antagonists pharmacology
Animals
Avoidance Learning drug effects
Benzazepines administration & dosage
Benzazepines pharmacology
CA1 Region, Hippocampal physiology
Catheterization
Dopamine Antagonists administration & dosage
Dopamine Antagonists pharmacology
Excitatory Amino Acid Antagonists administration & dosage
Excitatory Amino Acid Antagonists pharmacology
Fear drug effects
Histamine H2 Antagonists administration & dosage
Histamine H2 Antagonists pharmacology
Male
Microinjections
Ranitidine adverse effects
Ranitidine pharmacology
Rats
Rats, Wistar
Timolol pharmacology
Amygdala drug effects
Extinction, Psychological drug effects
Fear psychology
Hippocampus drug effects
Motivation drug effects
Prefrontal Cortex drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1872-7549
- Volume :
- 232
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Behavioural brain research
- Publication Type :
- Academic Journal
- Accession number :
- 22525015
- Full Text :
- https://doi.org/10.1016/j.bbr.2012.04.015